title: Concentration and high avidity of pneumococcal antibodies persist at least 4 years after immunization with pneumococcal conjugate vaccine in infancy.
abstract: To provide more extensive evidence of long-term effects of vaccination on immunity against Streptococcus pneumoniae, a follow-up study of the Finnish Otitis Media (FinOM) Vaccine Trial was conducted. One of the objectives was to assess the persistence and avidity of pneumococcal antibodies 4 years after pneumococcal vaccination given in infancy. Children with complete follow-up in the FinOM trial up to 24 months of age were invited to a single visit in their fifth year of life. A blood sample was taken from all children for determination of anticapsular antibody concentrations to vaccine serotypes and avidity of antibodies to three serotypes. Children had been vaccinated at 2, 4, 6, and 12 months of age with 7-valent pneumococcal capsular polysaccharide, CRM197 conjugate vaccine (PCV7), or a control vaccine. Serum IgG antibody concentrations to vaccine serotypes remained significantly higher in children who had received PCV7 than in control children for 4 years after the fourth PCV7 dose. Concentrations of antibodies to frequently carried serotypes (6B and 19F) declined less than those of antibodies to a rarely carried serotype (4), suggesting that natural boosting contributed to antibody persistence. Furthermore, antibody avidity was significantly higher in PCV7 than control vaccine recipients. Four doses of PCV7 given in infancy elicit long-lasting antibody responses with high avidity. (This study has been registered at ClinicalTrials.gov under registration no. NCT00378417.).
authors: National Institute for Health and Welfare THL, Helsinki, Finland. nina.ekstrom@thl.fi
authors: Nina
authors: N
authors: Ekström
authors: Heidi
authors: H
authors: Ahman
authors: Arto
authors: A
authors: Palmu
authors: Sinikka
authors: S
authors: Grönholm
authors: Terhi
authors: T
authors: Kilpi
authors: Helena
authors: H
authors: Käyhty
mesh_terms: D000907:Antibodies, Bacterial / Q000097:blood*; D000915:Antibody Affinity; D002675:Child, Preschool; D005260:Female; D005387:Finland; D005500:Follow-Up Studies; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D007114:Immunization / Q000379:methods*; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D008297:Male; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D013296:Streptococcus pneumoniae / Q000276:immunology*; D013997:Time Factors
chemical_list: D000907:Antibodies, Bacterial; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines
references: Pediatr Infect Dis J. 1998 Mar;17(3):211-6
references: 9535248
references: J Infect Dis. 1998 Apr;177(4):1112-5
references: 9534995
references: J Infect Dis. 1995 Nov;172(5):1273-8
references: 7594664
references: Expert Rev Vaccines. 2009 Nov;8(11):1479-500
references: 19863240
references: Pediatr Infect Dis J. 2006 Apr;25(4):312-9
references: 16567982
references: Vaccine. 2007 Mar 22;25(13):2451-7
references: 17023095
references: Clin Diagn Lab Immunol. 2001 Mar;8(2):266-72
references: 11238206
references: Vaccine. 2001 Oct 12;20(1-2):194-201
references: 11567764
references: JAMA. 1992 Mar 18;267(11):1489-94
references: 1538539
references: Infect Immun. 2005 Jan;73(1):369-77
references: 15618174
references: Lancet. 2005 Mar 26-Apr 1;365(9465):1139-46
references: 15794968
references: N Engl J Med. 2003 Oct 2;349(14):1341-8
references: 14523142
references: J Infect Dis. 2009 Apr 15;199(8):1168-76
references: 19265481
references: Vaccine. 2004 Dec 2;23(3):298-304
references: 15530671
references: Pediatr Infect Dis J. 2003 Jan;22(1):10-6
references: 12544402
references: Vaccine. 2004 Jul 29;22(21-22):2696-700
references: 15246599
references: Pediatrics. 2010 May;125(5):866-75
references: 20435707
references: J Infect Dis. 2006 Dec 15;194(12):1745-52
references: 17109348
references: Lancet. 2003 Aug 2;362(9381):355-61
references: 12907008
references: Clin Vaccine Immunol. 2008 Sep;15(9):1391-7
references: 18596205
references: Pediatr Infect Dis J. 2011 Sep;30(9):e155-63
references: 21572373
references: Lancet. 2009 Sep 12;374(9693):893-902
references: 19748398
references: Pediatr Infect Dis J. 2000 Mar;19(3):187-95
references: 10749457
references: Pediatr Infect Dis J. 2004 Aug;23(8):732-8
references: 15295223
references: Clin Infect Dis. 2008 Jan 15;46(2):186-92
references: 18171249
references: J Infect Dis. 2001 Sep 1;184(5):661-2
references: 11494176
references: Vaccine. 2007 Mar 1;25(11):1953-61
references: 17258358
references: Infect Immun. 1999 May;67(5):2366-70
references: 10225896
references: Eur J Pediatr. 2002 Dec;161 Suppl 2:S127-31
references: 12494258
references: N Engl J Med. 2001 Feb 8;344(6):403-9
references: 11172176
references: Clin Infect Dis. 2003 Nov 1;37(9):1155-64
references: 14557958